Stratum Corneum Deposition Mechanics at the Nano-Scale: How Carrier Size Shapes Delivery Pathway

The relationship between nanoparticle diameter and stratum corneum deposition pathway – and why NanoBase™ tri-domain architecture exploits three simultaneous deposition mechanisms that single-carrier systems cannot access.

DOI Reference: 10.5281/zenodo.18616576

The Stratum Corneum as a Nano-Scale Selective Barrier

The stratum corneum (SC) is a 10-20 μm barrier comprising 15-25 layers of terminally differentiated corneocytes embedded in a structured lipid matrix. This “brick and mortar” architecture creates three distinct surface transport pathways: intercellular (between corneocytes through lipid lamellae), transcellular (through corneocytes), and appendageal (via hair follicles and sweat glands). At the macro-scale, conventional formulations rely primarily on passive diffusion governed by Fick’s law, with surface uptake determined by partition coefficient and molecular weight. At the nano-scale, carrier diameter becomes the primary determinant of which pathway dominates.

Particles above 500 nm remain on the skin surface without engaging deeper intercellular structures. Between 200-500 nm, carrier-skin interaction occurs primarily through appendageal structures (follicular and furrow deposition). Below 200 nm, intercellular lipid-channel engagement becomes accessible within the stratum corneum itself. NanoBase™ operates in the 125-195 nm range (DLS-characterised, DOI: 10.5281/zenodo.18616576), engineered for deposition into the stratum corneum’s intercellular lipid architecture as the primary mechanism.

Intercellular Lipid Channel Architecture and Carrier Compatibility

SC intercellular channels are organized as repeating lipid bilayers composed primarily of ceramides (ceramide NP, ceramide AP, ceramide EOS), cholesterol, and free fatty acids (predominantly lignoceric acid, C24:0). These lamellae maintain a characteristic repeat distance of approximately 13 nm (long periodicity phase) and 6 nm (short periodicity phase). For a nanoparticle to engage this matrix, it must either occupy the aqueous domains between lamellae or transiently interact with the lipid organization at the surface.

NanoBase™ tri-domain carriers are engineered for compatibility with this architecture. The nanoemulsion domain (oil-continuous, ~150-195 nm) carries lipophilic actives and interacts favorably with the SC lipid matrix through hydrophobic compatibility. The nanoliposomal domain (phospholipid bilayer vesicles, ~125-170 nm) mimics native SC lipid organization and can integrate into the lamellar structure at the surface. The nanomicellar domain (surfactant-stabilized, ~130-165 nm) creates transient aqueous channel expansion that facilitates hydrophilic cargo association with the intercellular matrix.

Why Single-Carrier Systems Fail at Multi-Active Delivery

Traditional nano-delivery platforms employ a single carrier type - typically either a nanoemulsion or a liposomal system. This forces all actives, regardless of their physicochemical properties (log P, molecular weight, charge state), through one deposition mechanism. A hydrophilic peptide (e.g., palmitoyl tripeptide-1, MW ~623 Da, water-soluble) loaded into a nanoemulsion will exhibit poor encapsulation efficiency and rapid premature release before reaching the intended surface target. Conversely, a lipophilic active (e.g., retinol, log P ~6.3) loaded into a nanomicellar system will partition out of the hydrophilic core and accumulate at the carrier surface.

The NanoBase™ tri-domain architecture resolves this incompatibility by assigning each active ingredient to its optimal carrier domain based on physicochemical profiling: lipophilic actives (log P > 3) to the nanoemulsion domain, amphiphilic actives to the nanoliposomal domain, and hydrophilic actives (log P < 1) to the nanomicellar domain. Each domain then engages the SC via its mechanistically optimal pathway, depositing actives at their target zone without cross-domain interference.

Functional Category and Target Skin Layer

Different active categories have different functional targets within the skin’s outer layers, and carrier domain assignment should reflect that rather than treating all actives identically. Anti-aging peptides (e.g., palmitoyl tripeptide-1, copper peptides) perform best when deposited within the lower stratum corneum, positioned to support the skin’s own surface barrier and signaling processes. Antioxidants function effectively with upper SC-level deposition, positioned to intercept surface oxidative stress. Hydrating and humectant actives benefit from distribution throughout the SC depth, supporting surface water-binding capacity. NanoBase™ multi-domain deposition assigns each functional category to the carrier domain best matched to its target zone within the stratum corneum, rather than forcing every active through one uniform release profile.

Temperature and Hydration Effects on Nano-Scale Deposition

SC barrier function is not static. Skin temperature (typically 32°C at the surface) increases lipid fluidity in the intercellular matrix, widening effective channel dimensions. Occlusion or high ambient humidity increases SC hydration, swelling corneocytes and expanding intercellular spaces. Both conditions enhance nano-scale deposition - a factor that NanoBase™ formulation protocols account for during efficacy testing by specifying both occluded and non-occluded deposition conditions at controlled temperature (32 ± 1°C).

For brand partners developing product claims, this means deposition data generated under non-physiological conditions (room temperature, non-occluded) systematically underestimates in-use performance. NanoBase™ efficacy protocols simulate actual use conditions - post-cleansing skin temperature, typical ambient humidity, and realistic application thickness - to generate deposition data that accurately reflects consumer experience.

Implications for Formulation Design

Understanding SC deposition mechanics at the nano-scale eliminates the guesswork from delivery system design. Rather than optimizing a single carrier and hoping for adequate deposition, NanoBase™ tri-domain architecture assigns each active to a carrier domain matched to its target zone and physicochemical profile. The result is predictable, reproducible deposition, verified by DLS particle sizing and released against its engineered multi-angle distribution signature rather than a single dispersity figure, and supported by published technical documentation (DOI: 10.5281/zenodo.18616576). For formulators transitioning from legacy HLB-based systems, this represents a paradigm shift from empirical optimization to engineered delivery.